If you or a loved one lives with diabetes, you already know how critical and sometimes expensive insulin can be. For many Medicare enrollees, the high cost of insulin has been a burden for years, forcing some people to ration their doses or even skip them altogether. But in recent years, there’s been a big shift toward making insulin more affordable, thanks to the Inflation Reduction Act (IRA).

The IRA brought immediate relief back in 2023 with a hard cap on monthly insulin costs. But the good news doesn’t stop there starting in January 2026, the savings could become even greater. Let’s walk through what’s changing, why it matters, and what it could mean for you or someone you care about.

 

A Quick Recap: The 2023 Insulin Cap

In 2023, the IRA put into place a simple but powerful rule: no one on Medicare should pay more than $35 a month for insulin.

That cap applied to both Medicare Part B (insulin delivered through an insulin pump) and Medicare Part D (insulin you pick up at the pharmacy). Just as important, the law required insulin to be covered before you meet your deductible.

In plain terms, this meant you didn’t have to pay out of pocket until you hit a deductible before insulin coverage kicked in the $35 cap applied right away.

For millions of older adults and people with disabilities, this was life-changing. It gave peace of mind, knowing that at the pharmacy counter, the price tag for insulin would not spiral out of control.

 

What’s Coming in 2026

While the $35 monthly cap is helpful, the IRA built in another phase of improvements starting in January 2026. The idea is to make insulin costs even more flexible, giving Medicare enrollees access to the lowest possible price.

Here’s how it will work:

When you go to fill your insulin prescription, you’ll pay the lesser of these three options:

1. $35 flat cap; the current protection stays in place.
2. 25% of the maximum fair price; this is a new benchmark created by the Medicare Drug Price Negotiation Program, which gives Medicare the power to negotiate directly with drugmakers.
3. 25% of the negotiated price under your plan; whether you’re enrolled in a standalone Medicare Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD), your cost could be tied to the discounted price negotiated by your plan.

This might sound a little technical, but the key takeaway is simple: instead of being stuck at $35, you could pay even less if negotiated prices or fair prices fall below that amount.

 

Why This Matters for Patients

For someone who uses insulin every day, the difference between $35 and, say, $20 a month may not sound huge on paper. But think about it across a year, that’s almost $200 in savings. And for people managing multiple prescriptions, every dollar counts.

Here are a few reasons this change matters so much:

• Reduces financial stress: Diabetes already comes with doctor visits, testing supplies, and other medications. Lower insulin costs ease the monthly financial pressure.
• Encourages consistent use: Unfortunately, stories of people rationing insulin because of cost have made headlines for years. These new protections reduce that risk, making it easier for patients to stick to their prescribed doses.
• Brings fairness to pricing: Insulin has been around for more than a century, yet its cost has skyrocketed in the U.S. compared to other countries. The IRA’s negotiation program aims to fix that imbalance.
• Predictability: Knowing your insulin won’t suddenly shoot up in price allows people to budget and plan better, especially those on fixed incomes.

 

The Bigger Picture: Why Insulin Costs Have Been So High

To really appreciate these changes, it helps to understand the backdrop. Insulin isn’t new, it was discovered in the 1920s. In fact, the researchers who developed it sold the patent for just $1, hoping it would remain accessible to all.

Fast forward to recent decades, and insulin prices in the U.S. have soared. According to health policy researchers, some people were paying hundreds of dollars per month for a single type of insulin. Drugmakers, middlemen (like pharmacy benefit managers), and the complexities of the healthcare system all contributed to this inflated cost.

That’s why the IRA’s changes are such a big deal. By capping costs and, eventually, giving Medicare the power to negotiate directly with manufacturers, the government is trying to chip away at a system that has been financially crushing for many families.

 

What You Can Do as 2026 Approaches

If you or someone you love uses insulin, here are a few practical steps to keep in mind:

1. Review your Medicare plan each year. Even with caps in place, different plans may have slightly different negotiated prices or coverage rules. Open Enrollment (October 15 – December 7 each year) is your chance to make sure you’re in the most affordable plan for your needs.
2. Talk to your doctor about your insulin type. Not all insulin products cost the same, and some may fall under negotiated price reductions faster than others. Your doctor can help you understand your options.
3. Stay informed about the Drug Price Negotiation Program. The government will publish lists of drugs subject to negotiated prices, and insulin products are likely to be among them. Keeping up with these announcements will help you know what to expect.
4. Keep receipts and track costs. If you notice inconsistencies at the pharmacy counter, having records makes it easier to resolve billing issues with your plan.

 

Looking Ahead

The 2023 cap was just the start. With the new rules in 2026, insulin could become even more affordable, and Medicare beneficiaries will finally get to benefit from fairer pricing structures.

Of course, policy changes can sometimes feel like alphabet soup, Part B, Part D, PDPs, MA-PDs, fair prices, negotiated prices, but the core message is clear: insulin is becoming more affordable, and that affordability is here to stay.

For millions of people managing diabetes, that means less financial strain, fewer skipped doses, and more peace of mind. And that’s a win worth celebrating.